Analysis reveals improved risk assessment in localized lung cancer, suggesting ctDNA and radiomics enhance predictive models.
Anonymized clinical and demographic data, cell-free DNA metrics, somatic mutation data, radiomic, biological, and molecular metrics, and CIRI-LCRT predicted progression-free survival.
No takes yet. Share an insight, caveat, or question.
Moding et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: